Regenxbio RGNX
$7.16 −$0.02 (-0.28%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.12 -0.56%
Open$7.00
Prev close$7.18
Day range$6.86 – $7.30
Volume1.06M
Market cap$473.44M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$9.16M-69.2% YoY
Operating profit-$73.56M-40.4% YoY
Net profit-$40.74M+34.2% YoY
Diluted EPS-$0.62+48.3% YoY
Free cash flow$38.42M+168.1% YoY
Operating cash flow$38.61M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin87.5%
Operating margin-120.4%
Net margin-113.9%
Return on equity-113.2%
Return on assets-35.4%
Return on invested capital-61.5%
Current ratio4.74
Liabilities / assets68.2%
Cash & investments$250.98M
Total debt$60.05M
Net cash (debt)$190.92M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $9.16M | $108.02M | $6.39M | $170.44M | $30.34M |
| Total Operating Revenue | $9.16M | $108.02M | $6.39M | $170.44M | $30.34M |
| Cost of Revenue | $1.14M | $1.04M | $11.07M | $20.30M | $5.93M |
| Gross Profit | $8.02M | $106.98M | -$4.68M | $150.14M | $24.41M |
| Operating Expense | $81.58M | $77.71M | $78.68M | $311.34M | $82.05M |
| Selling and Admin Expenses | $20.58M | $21.62M | $21.31M | $82.86M | $22.38M |
| -General & Admin Expense | $20.58M | $21.62M | $21.31M | $82.86M | $22.38M |
| Research & Development | $61.01M | $56.09M | $57.34M | $228.30M | $59.61M |
| Other Operating Expenses | -$7,000.00 | $12,000.00 | $36,000.00 | $179,000.00 | $54,000.00 |
| Operating Profit | -$73.56M | $29.26M | -$83.36M | -$161.20M | -$57.64M |
| Net Non-Operating Interest Income (Expense) | -$7.46M | -$7.78M | -$8.69M | -$44.93M | -$12.26M |
| Non-Operating Interest Income | $16,000.00 | $17,000.00 | $16,000.00 | $83,000.00 | $18,000.00 |
| Non-Operating Interest Expense | $7.47M | $7.79M | $8.71M | $45.01M | $12.28M |
| Other Income (Expense) | $40.28M | $1.22M | $2.00M | $12.25M | $2.75M |
| Gain on Sale of Security | $2.25M | $1.22M | $2.00M | $12.25M | $2.75M |
| Special Income (Charges) | $38.03M | – | – | $0.00 | $0.00 |
| -Less:Other Special Charges | -$38.03M | – | – | – | – |
| Pretax Profit | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Net Profit | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Profit from Continuing Operations | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Net Income to Parent Company | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Net Income to Common Stockholders | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Basic EPS | -$0.62 | $0.43 | -$1.72 | -$3.76 | -$1.30 |
| Diluted EPS | -$0.62 | $0.43 | -$1.72 | -$3.76 | -$1.30 |
| Asset Impairment Loss | – | – | – | $0.00 | – |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $466.04M | $386.62M | $341.89M | $453.03M | $453.03M |
| Total Current Assets | $320.89M | $236.16M | $186.52M | $281.28M | $281.28M |
| Cash and Cash Equivalents & Short-Term Investments | $250.98M | $105.52M | $150.49M | $230.07M | $230.07M |
| -Cash and Cash Equivalents | $95.80M | $36.49M | $15.23M | $34.47M | $34.47M |
| -Short Term Investments | $155.18M | $69.03M | $135.26M | $195.60M | $195.60M |
| Receivables | $9.50M | $107.10M | $10.94M | $27.38M | $27.38M |
| -Accounts Receivable | $1.17M | $100.39M | $2.80M | $557,000.00 | $557,000.00 |
| -Accrued Interest Receivable | $961,000.00 | $348,000.00 | $902,000.00 | $1.00M | $1.00M |
| -Other Receivables | $7.36M | $6.37M | $7.24M | $25.82M | $25.82M |
| Prepaid Assets | $13.01M | $11.90M | $11.54M | $11.93M | $11.93M |
| Restricted Cash | $225,000.00 | $225,000.00 | – | – | – |
| Other Current Assets | $47.19M | $11.41M | $13.54M | $11.90M | $11.90M |
| Total Non-Current Assets | $145.15M | $150.46M | $155.38M | $171.75M | $171.75M |
| Net PPE | $137.59M | $142.32M | $147.42M | $152.01M | $152.01M |
| -Gross PPE | $234.58M | $236.25M | $238.42M | $239.20M | $239.20M |
| -Accumulated Depreciation | -$96.99M | -$93.93M | -$91.01M | -$87.19M | -$87.19M |
| Investments and Advances | $0.00 | $0.00 | $0.00 | $10.79M | $10.79M |
| Non Current Accounts Receivables | $450,000.00 | $435,000.00 | $420,000.00 | $2.31M | $2.31M |
| Other Non-Current Assets | $7.11M | $7.71M | $7.54M | $6.64M | $6.64M |
| Total Liabilities | $318.00M | $314.85M | $320.81M | $350.30M | $350.30M |
| Total Current Liabilities | $67.68M | $82.62M | $71.11M | $118.10M | $118.10M |
| Payables | $13.48M | $15.55M | $21.21M | $21.36M | $21.36M |
| -Accounts Payable | $13.48M | $15.55M | $21.21M | $21.36M | $21.36M |
| Current Accrued Expenses | $13.57M | $10.11M | $12.53M | $20.97M | $20.97M |
| Short-Term Debt and Capital Lease Obligation | $6.49M | $7.36M | $7.87M | $8.29M | $8.29M |
| -Current Capital Lease Obligation | $6.49M | $7.36M | $7.87M | $8.29M | $8.29M |
| Current Deferred Liabilities | $5.99M | $9.88M | $5.92M | $10.45M | $10.45M |
| Other Current Liabilities | $12.11M | $26.77M | $14.23M | $39.61M | $39.61M |
| Total Non-Current Liabilities | $250.31M | $232.23M | $249.70M | $232.20M | $232.20M |
| Long Term Debt and Capital Lease Obligation | $60.05M | $61.60M | $63.20M | $65.22M | $65.22M |
| -Long Term Capital Lease Obligation | $60.05M | $61.60M | $63.20M | $65.22M | $65.22M |
| Non-Current Deferred Liabilities | $16.22M | $15.40M | $22.78M | $18.94M | $18.94M |
| Other Non-Current Liabilities | $174.04M | $155.23M | $163.73M | $148.05M | $148.05M |
| Total Equity | $148.04M | $71.77M | $21.08M | $102.73M | $102.73M |
| Stockholders' Equity | $148.04M | $71.77M | $21.08M | $102.73M | $102.73M |
| Capital Stock | $7,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| -Common Stock | $7,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.38B | $1.27B | $1.24B | $1.23B | $1.23B |
| Retained Earnings | -$1.23B | -$1.19B | -$1.22B | -$1.13B | -$1.13B |
| Gains/Losses Not Affecting Retained Earnings | -$1.05M | -$875,000.00 | -$870,000.00 | -$687,000.00 | -$687,000.00 |
| -Available for Sale Securities | – | – | – | $10.79M | $10.79M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $38.61M | -$62.24M | -$76.19M | -$123.96M | -$52.29M |
| Net cash flow from continuing operations | $38.61M | -$62.24M | -$76.19M | -$123.96M | -$52.29M |
| Net Income from Continuing Operations | -$40.74M | $22.71M | -$90.05M | -$193.88M | -$67.15M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | -$62,000.00 | $0.00 |
| Depreciation & Depletion & Amortization | $3.52M | $3.76M | $3.86M | $15.62M | $3.87M |
| Other Non-Cash Items | $7.48M | $5.54M | $2.89M | $13.50M | $5.64M |
| Change in Working Capital | $61.91M | -$103.28M | -$1.50M | $11.78M | -$1.80M |
| -Change in Receivables | $98.22M | -$96.71M | $18.25M | -$7.66M | -$561,000.00 |
| -Change in Prepaid Assets | -$1.11M | -$361,000.00 | $384,000.00 | -$2.86M | $1.02M |
| -Change in Payables and Accrued Expense | $4.46M | -$4.12M | -$16.39M | -$2.06M | -$1.82M |
| -Change in Other Current Assets | -$34.17M | $3.57M | -$509,000.00 | $6.70M | $7.56M |
| -Change in Other Current Liabilities | -$2.42M | -$2.25M | -$2.54M | -$11.62M | -$3.02M |
| -Change In Other Working Capital | -$3.08M | -$3.41M | -$700,000.00 | $29.28M | -$4.99M |
| Net cash flow from investing | -$86.15M | $65.93M | $70.59M | -$15.87M | $37.54M |
| Net Cash Flow from Continuing Investing Activities | -$86.15M | $65.93M | $70.59M | -$15.87M | $37.54M |
| Net PPE Purchase and Sale | -$194,000.00 | -$760,000.00 | -$1.24M | -$2.41M | -$508,000.00 |
| Net Investment Purchase and Sale | -$85.96M | $66.69M | $71.82M | -$13.45M | $38.05M |
| Financing Cash Flow | $106.85M | $17.57M | -$13.64M | $116.77M | -$9.58M |
| Net Cash Flow from Continuing Financing Activities | $106.85M | $17.57M | -$13.64M | $116.77M | -$9.58M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $144.49M | $0.00 |
| Net Common Stock Issuance | $108.67M | $19.50M | $648,000.00 | $1.05M | $0.00 |
| Proceeds from Stock Option Exercised | $647,000.00 | $51,000.00 | $146,000.00 | $318,000.00 | $90,000.00 |
| Net Other Financing Charges | -$2.47M | -$1.98M | -$14.43M | -$29.09M | -$9.67M |
| Ending Cash Balance | $97.83M | $38.52M | $17.26M | $36.50M | $36.50M |
| Net Change in Cash | $59.31M | $21.26M | -$19.24M | -$23.06M | -$24.34M |
| Beginning Cash Balance | $38.52M | $17.26M | $36.50M | $59.56M | $60.83M |
| Free Cash Flow | $38.42M | -$63.00M | -$77.42M | -$126.38M | -$52.80M |
No comments yet — be the first to weigh in on RGNX.
Sign in to join the discussion.